According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “
Other equities research analysts have also issued reports about the company. HC Wainwright increased their price target on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Oppenheimer assumed coverage on Dova Pharmaceuticals in a research report on Thursday, August 29th. They issued an “outperform” rating and a $30.00 price target for the company. BidaskClub lowered Dova Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 17th. JPMorgan Chase & Co. increased their price target on Dova Pharmaceuticals from $13.00 to $15.00 and gave the company an “underweight” rating in a research report on Friday, July 12th. Finally, Evercore ISI raised Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price target for the company in a research report on Monday, July 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Dova Pharmaceuticals has an average rating of “Buy” and an average target price of $24.57.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.03). The company had revenue of $3.52 million during the quarter, compared to analysts’ expectations of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative return on equity of 101.60%. On average, research analysts expect that Dova Pharmaceuticals will post -2.43 EPS for the current year.
In other news, CEO David Zaccardelli sold 10,450 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $15.94, for a total transaction of $166,573.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Life Sciences Maste Perceptive bought 427,209 shares of the firm’s stock in a transaction dated Friday, June 28th. The shares were acquired at an average cost of $13.35 per share, with a total value of $5,703,240.15. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 610,916 shares of company stock valued at $8,689,169 and have sold 27,807 shares valued at $422,464. Company insiders own 60.30% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Capital Investment Advisory Services LLC increased its position in shares of Dova Pharmaceuticals by 222.2% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 2,900 shares of the company’s stock valued at $45,000 after purchasing an additional 2,000 shares during the last quarter. Quantamental Technologies LLC increased its position in shares of Dova Pharmaceuticals by 1,100.0% during the 2nd quarter. Quantamental Technologies LLC now owns 2,400 shares of the company’s stock valued at $34,000 after purchasing an additional 2,200 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Dova Pharmaceuticals by 22.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock valued at $336,000 after purchasing an additional 2,400 shares during the last quarter. Doyle Wealth Management purchased a new stake in shares of Dova Pharmaceuticals during the 2nd quarter valued at $49,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Dova Pharmaceuticals by 6.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 67,386 shares of the company’s stock valued at $951,000 after purchasing an additional 3,992 shares during the last quarter. 32.18% of the stock is owned by hedge funds and other institutional investors.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Featured Story: What are gap-down stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.